← All trials
NCT01385644
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2010
- Primary completion
- May 31, 2013
- Completion date
- May 31, 2013
- First posted
- Jun 30, 2011
- Last posted
- Dec 29, 2015
- Enrollment
- 8
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of QueenslandLead sponsor
- University of QueenslandOverall official - principal investigator
- University of QueenslandReponsible party - principal investigator
- University of QueenslandOfficial
- Mater Medical Research InstituteCollaborator
- University of QueenslandSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.